Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma

BACKGROUND: High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Graf, S. A., Stevenson, P. A., Holmberg, L. A., Till, B. G., Press, O. W., Chauncey, T. R., Smith, S. D., Philip, M., Orozco, J. J., Shustov, A. R., Green, D. J., Libby, E. N., Bensinger, W. I., Pagel, J. M., Maloney, D. G., Zhou, Y., Cassaday, R. D., Gopal, A. K.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4621031/
https://ncbi.nlm.nih.gov/pubmed/26347113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv364
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars